In this study, we investigated the genetic determinants of high telomeric content across 13555 sarcoma samples in the Foundation Medicine dataset and found that samples with high telomeric content were enriched in deletions in RAD51B, amplifications in GID4 (17p11.2), and short variant mutations in POT1 within select disease ontologies. This evidence concerns the gene GID4 and sarcoma.